1. Anderson RJ, Linas SL, Berns AS, et al. Nonoliguric acute renal failure. N Engl J Med 1997;296:1134–1138.
2. Cho JY, Jeong MH, Park SH, et al. Effect of contrast-induced nephropathy on cardiac outcomes after use of nonionic isosmolar contrast media during coronary procedure. J Cardiol 2010;56:300–306.
3. Pannu N, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006;295:2765–2779.
4. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994;45:259–265.
5. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005;68:14–22.
6. McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin 2005;21:261–280.
7. Choi W, Lim HM, Won HJ, et al. Contrast-induced nephropathy in patients undergoing percutaneous coronary angiography and its clinical characteristics. Korean J Nephrol 2008;27:55–61.
8. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983;74:243–248.
9. Laskey WK, Jenkins C, Selzer F, et al. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 2007;50:584–590.
10. Szummer K, Lundman P, Jacobson SH, et al. Cockcroft-Gault is better than the Modification of Diet in Renal Disease study formula at predicting outcome after a myocardial infarction: data from the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART). Am Heart J 2010;159:979–986.
11. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008;51:1419–1428; Erratum in: J Am Coll Cardiol 2008;51:2197.
12. Zijlstra F, de Boer MJ, Hoorntje JC, Reiffers S, Reiber JH, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680–684.
13. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection: Multivessel Angioplasty Prognosis Study Group. Circulation 1990;82:1193–1202.
14. Kim YS, Song SW, Ku YM, et al. Clinical characteristics and risk factors of contrast dye nephrotoxicity in patients performing arteriography. Korean J Nephrol 2004;23:248–255.
15. Cho YS, Chung TN, Sohn DK, Kim SH. Contrast nephrotoxicity associated with emergency CT scans. J Korean Soc Emerg Med 2003;14:157–161.
16. Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization: a prospective trial. Ann Intern Med 1989;110:119–124.
17. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989;86(6 Pt 1):649–652.
18. Shaper AG, Wannamethee SG, Whincup PH. Serum albumin and risk of stroke, coronary heart disease, and mortality: the role of cigarette smoking. J Clin Epidemiol 2004;57:195–202.
19. Vuong TD, Braam B, Willekes-Koolschijn N, Boer P, Koomans HA, Joles JA. Hypoalbuminaemia enhances the renal vasoconstrictor effect of lysophosphatidylcholine. Nephrol Dial Transplant 2003;18:1485–1492.
20. Nikolsky E, Mehran R, Lasic Z, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kindey Int 2005;67:706–713.